Introduction

Securities class action litigation has been filed on behalf of investors who purchased or otherwise acquired the common stock of Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) between March 5, 2024 and October 28, 2025, inclusive (the “Class Period”).

If you purchased or acquired Avantor common stock during the Class Period, you may move the Court for appointment as lead plaintiff by no later than December 29, 2025.

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Avantor investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should complete the form below, text or email investorinfo@lchb.com, or call Lieff Cabraser partner Sharon M. Lee at 1-800-541-7358.

Avantor, incorporated in Delaware and headquartered in Radnor, Pennsylvania, is a global supplier of scientific products, tools, laboratory solutions, and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries.

The action alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Avantor’s competitive positioning was weaker than Defendants had publicly represented; and (2) Avantor was experiencing negative effects from increased competition. Rather, Defendants repeatedly claimed that Avantor was well-positioned compared to peer companies and downplayed any competitive pressures.  For example, Defendant Michael Stubblefield, Avantor’s then-President and CEO, stated during a Company earnings call with investors and analysts that Avantor’s “lab business stacks up well against every number that certainly that we’ve seen,” and that “we’re really confident in our value proposition and our competitive position.” Defendants also touted Avantor’s purported competitive advantages, including its digital capabilities, that Defendants claimed supported Avantor’s strong competitive positioning.

The market began to learn the truth on April 25, 2025, when Avantor reported disappointing 1Q 2025 financial results, including weak organic sales for its Laboratory Solutions business, and cut its projected organic revenue growth for 2025 by 2% to -1% to 1%. Avantor also announced that Defendant Stubblefield would be stepping down from his roles. Avantor’s Executive Vice President and CFO, Defendant R. Brent Jones, attributed the Company’s weak performance and outlook in part to “the impact of increased competitive intensity.” On this news, the price of Avantor common stock declined $2.57 per share, or 16.58%, from a close of $15.50 per share on April 24, 2025, to close at $12.93 per share on April 25, 2025, on extremely heavy trading volume.

On August 1, 2025, Avantor reported disappointing 2Q 2025 financial results, including a 3% year-over-year decrease in net sales and an 11.7% year-over-year decrease in adjusted operating income in its Laboratory Solutions business. The Company also lowered its projected organic revenue growth for 2025 to -2% to 0%, and to -4% to -2% for 3Q 2025. Jones again attributed the reduced outlook and growth to “increased competitive intensity.” On this news, the price of Avantor common stock declined $2.08 per share, or 15.48%, from a close of $13.44 per share on July 31, 2025, to close at $11.36 per share on August 1, 2025, on extremely heavy trading volume.

On October 29, 2025, Avantor reported disappointing 3Q 2025 financial results, including a 5% year-over-year decrease organic revenue growth both in its Laboratory Solutions business and overall. Avantor further reduced its 2025 projected organic revenue growth -3.5% to -2.5%, and reported a noncash goodwill impairment charge of $785 million. Jones disclosed that the impairment charge was due in part to competitive pressures on the Company’s “ability to get price, which meaningfully impacted margins year-over-year on a sequential basis.” New President and CEO Emmanuel Ligner disclosed that the Company had “lost a couple of large accounts.” On this news, the price of Avantor common stock declined $3.50 per share, or 23.21%, from a close of $15.08 per share on October 28, 2025, to close at $11.58 per share on October 29, 2025, on heavy trading volume.

Read our Securities and Investment Fraud Practice Area brochure